Calcium acetate

Concise Prescribing Info
Control of hyperphosphataemia in ESRD.
Dosage/Direction for Use
Adult : PO Initial: 4-8 g (1-2 g Ca)/day in divided doses, adjusted according to serum phosphate concentrations. Max: 12 g (3 g Ca)/day.
Dosage Details
Adult: Control of hyperphosphataemia in ESRD: Initially, 4-8 g (1-2 g Ca) daily in divided doses, adjusted according to serum phosphate concentrations. Max: 12 g (3 g Ca) daily.
Should be taken with food.
Hypercalcaemia, renal calculi.
Special Precautions
Patient with hypercalcaemia-associated diseases (e.g. sarcoidosis, and other malignancies); risk factors for cardiac arrhythmias, hypoparathyroid disease. Renal impairment. Pregnancy.
Adverse Reactions
Significant: Hypercalcaemia, constipation, bloating and gas.
Gastrointestinal disorders: Nausea, vomiting.
Monitor serum Ca (twice weekly during initial dose adjustments); serum phosphorus; serum Ca-phosphorus product; intact parathyroid hormone.
Drug Interactions
Increased risk of cardiac arrhythmias with digitalis, verapamil, gallopamil in the presence of hypercalcaemia. May decrease the bioavailability of fluoroquinolones (e.g. ciprofloxacin), and tetracyclines (e.g. doxycycline).
Description: Ca acetate sequesters phosphate in the small intestine to form insoluble calcium phosphate, which is excreted in the faeces, thereby reducing phosphate absorption in the gut and preventing the development of renal osteodystrophy in chronic renal failure.
Absorption: Primarily absorbed from the small intestine via active transport and passive diffusion, vitamin D enhances absorption.
Distribution: Crosses the placenta and enters the breast milk.
Excretion: Mainly via faeces (as insoluble calcium salts); urine (20%).
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25°C.
ATC Classification
V03AE07 - calcium acetate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
Disclaimer: This information is independently developed by MIMS based on Calcium acetate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in